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Medline, PubMed, and EMBASE to identify full economic evaluations that com-
pared different treatment strategies in postmenopausal women with primary 
breast cancer. Quality and modelling methodologies of included studies were 
assessed and summarised. Results: All the 31 included studies assessed surgery 
and none assessed PET as the initial treatment. Most included economic stud-
ies used a Markov model with life-time horizon and 1-year cycle length. Nine 
studies which included sub-group analysis for older women (over 65 years old) 
used similar economic models and transition states with younger women (50 
to 65 years old). The key disease-related health states were disease-free, recur-
rence, and death. Recurrence was mostly separated into loco-regional and distant 
recurrence. ConClusions: This systematic review can inform the design of an 
economic model comparing PET with surgery as initial treatment in older women 
based on the following assumptions: (1) health states are applicable across age 
groups; (2) transition states for modelling surgery in the literature are transferable 
to model the same treatment for older women; (3) metastasis transition states 
including progression, progression-free, and death can be used to model the PET 
pathway. Future study will validate this model by using a longitudinal dataset of 
older women with primary breast cancer, and synthesize data from different data 
sources to populate this economic model.
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objeCtives: Colorectal cancer is the third most common cancer in Scotland, with 
nearly 4,000 cases reported in 2011 and 5.2% increase in incidence in the previous 
10 years. Recent studies have shown that a subgroup of metastatic colorectal cancer 
(mCRC) patients with wild-type (wt) RAS (KRAS and NRAS exons 2,3, 4) expressing 
tumours are likely to have enhanced response to anti-EGFR treatment compared 
to patients with mutant RAS exons (2,3, 4). RAS biomarkers aid identification of the 
patient group that is likely to benefit the most from anti-EGFR treatment such as 
cetuximab and therefore allow more efficient use of NHS Scotland resources. A New 
Product Assessment Form was submitted to the Scottish Medicines Consortium with 
the aim of demonstrating the latest improved outcomes in RAS wt mCRC patients 
(versus KRAS wt) treated with cetuximab in combination with chemotherapy and 
its cost effectiveness compared to currently available treatments. Methods: 
A state-transition Markov cohort model was developed to simulate patient outcomes 
and costs for first and subsequent lines of treatment including the long-term sur-
vival after a successful curative resection of liver metastases. Results: The model 
estimated an incremental 0.28 life-years gained (LYG) with cetuximab + FOLFIRI 
compared to FOLFIRI alone and an incremental 0.32 LYG with cetuximab + FOLFOX 
compared to FOLFOX alone. The model was most sensitive to length of treatment 
with cetuximab. ConClusions: The incremental cost effectiveness ratios imputed 
in the model are close to the traditional willingness to pay threshold adopted by 
the SMC. This analysis demonstrates that cetuximab in combination with FOLFIRI 
or FOLFOX in mCRC RAS wt patients is a cost-effective treatment compared with 
chemotherapy alone, specifically when taking into consideration that cetuximab 
qualifies as an end of life medicine (following SMC criteria) which raises the value 
of such intervention.
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The treatment of glioblastoma after first-line treatment progression is not clearly 
established in Spain. Most accepted alternatives are nitrosoureas (fotemustine, F), 
extended-dose temozolomide (eT) or bevacizumab (B). Without clear standards of 
care, increased clinical and health policy uncertainty among decision makers should 
be clarified. So, economic evaluation might reduce those uncertainties. objeCtives: 
To analyze the cost-effectiveness of bevacizumab, extended-dose temozolomide 
and fotemustine in patients with either recurrent or progressive glioblastoma after 
standard therapy, compared to standard clinical practice (SCP). Methods: A cost-
effectiveness markov model was conducted from a payer perspective (time horizon 
1 year, 3%, discount rate, 2012, € ). Our model got three health states: alive without 
progression, alive with toxicity and progression as absorbing state. We subsequently 
performed a deterministic and probabilistic analysis of sensitivity. Main efficacy 
outcome was progression-free survival at six months (6m PFS). Toxicity data was 
based on relevant phase II studies. Health state utility values were estimated based 
on published values from an HTA report by Garside et al, 2007. Costs were obtained 
from a Spanish University Hospital. Results: Cost/effectiveness ratios were: SCP 
(based on carmustine) 2,368.45 € /year to obtain 6m PFS with stable health state 
utility value, F 4,112.97 € /year, B 15,122.49 € /year and eT 5,470.05 € /year. Incremental 
cost-effectiveness ratios were: F 7,404.12 € /year € /year to obtain 6m PFS with stable 
health state utility value, B 40,371.8 € /year and eT 45,853.51 € /year. Tornado diagram 
and CEAC showed our results robustness. ConClusions: ICER analysis shows fote-
mustine to be the dominant option in the treatment of patients with recurrent or 
progressive glioblastoma.
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from each taxpayer. ConClusions: A cancer cure evaluated under current health 
economic evaluation methods would cause a budget impact that would be 
unaffordable for governments due to the high prices that could be achieved 
while remaining cost effective. Although these types of technologies therapies 
are not currently available, payers might want to explore new methods of evalu-
ation, as exploring the possibility of calculating costs based on quality adjusted 
lifetimes rather than years or increasing discount rates on QALYs for immuno-
therapies.
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objeCtives: To analyze the economic impact of the incorporation of pertuzumab 
for the treatment of metastatic breast cancer HER2+ in a University Hospital accord-
ing to real data of our patients. Methods: Cross-sectional study where the patients 
with breast cancer were analyzed in our hospital during one year (April 2013 to 
April 2014). The demographic data of the patients (age and weight) and antineo-
plastic treatments used were obtained from the computer program Hospiwin®. 
The dose and efficacy data have been obtained from the phase III CLEOPATRA trial. 
This clinical trial compares docetaxel + trastuzumab vs docetaxel + trastuzumab + 
pertuzumab with progression-free survival (PFS) 12.4 (CI 10.4-13.5) vs. 18.5 (CI 16.6-
21.6) months respectively. Costs of the drugs were included in the economic model 
developed in Excel® data base. The time horizon was one year and the perspective 
of medical leadership of the hospital was used. Results: During the study period 
371 patients were treated for breast cancer and 75 patients (20.2 %) were HER2+. The 
mean weight of 71.5 kg (SD = 17.1) and men BMI of 29.3 were obtained. The annual 
cost of docetaxel + trastuzumab + pertuzumab was 69,245.32 € vs 29,837.4 € (CI (in 
the docetaxel + trastuzumab treatment group. The cost per PFS per year was 44,964 
€ (CI 38,469-50,177 € ) in the docetaxel + trastuzumab + pertuzumab group vs 29,837 
(CI 26,640-35,948 € ) in the docetaxel + trastuzumab treatment group. The incremen-
tal cost effectiveness ratio (ICER) was 15.127 € /PFS per year. ConClusions: The 
addition of pertuzumab to treatment with docetaxel / trastuzumab for metastatic 
breast cancer has shown an increase in SLP. However, the economic impact of this 
new drug, requires careful selection of patients who could benefit. Health authori-
ties will have to consider whether pertuzumab is cost-effective in terms of their 
willgness to pay.
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objeCtives: Multitargeted receptor tyrosine kinase inhibitors are more effec-
tive alternatives to interferon-α and monoclonal antibodies in patients with 
metastatic renal cell carcinoma (mRCC). However, studies on the economic and 
humanistic outcomes associated with these treatments are sparse in the Chinese 
setting. This study evaluated the clinical and economic consequences of sunitinib 
compared with sorafenib and interferon-α from the third-party payer’s perspective 
in China. Methods: A Markov model was developed to simulate disease progres-
sion and determine cost and outcomes over patient’s lifetime. The time horizon 
of analysis was patients’ lifetime with a maximum of five years in cycles of six 
weeks. The model was used to conduct a cost-utility analysis on sunitinib compared 
to interferon-α and sorafinib. Costs of physician, anti-cancer medications, hospi-
talization, laboratory, and palliative care were estimated. Outcomes were meas-
ured in progression-free life years (PFLYs), life years (LYs) and quality-adjusted life 
years (QALYs). A 3.5% discount rate was applied to both costs and QALYs gained.  
Results: In the base case, the total cost of the sunitinib arm was RMB217,038.50, 
the progression-free life year was 1.57, life year was 2.55, and QALY was 1.70. The 
incremental cost per PFLY between sunitnib and IFN-α was –RMB78,562.10 and 
RMB 22,501.03 between sunitinib and sorafenib. The incremental cost per life year 
between sunitnib and IFN-α was –RMB168,633.00 and RMB 21,022.38 between suni-
tinib and sorafenib. The incremental cost per QALY between sunitnib and IFN-α was –
RMB184,825.00 and RMB 29,493.42 between sunitinib and sorafenib. ConClusions: 
This economic study used the final clinical results of the pivotal sunitinib trial that 
provides more accurate modeling results than previous studies based on extrapola-
tion. It was found that sunitinib was dominant compared to IFN-α . Sunitinib was 
cost effective compared to sorafenib based on the threshold recommended by the 
World Health Organization.
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objeCtives: Despite the lack of evidence-based information on their clinical and 
cost-effectiveness, surgery and primary endocrine therapy (PET) are the most 
commonly used initial treatment strategies for older women with primary breast 
cancer in the United Kingdom (UK). To evaluate the cost-effectiveness of PET and 
surgery, a decision analytical modelling is necessary. This systematic review aimed 
to summarise the modelling methodologies from the literature to inform the 
model design in older women. Methods: An electronic database search was 
conducted using NHS Economic Evaluation Database, Cochrane Library, Ovid 
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ment regimens for chronic myeloid leukemia. If further research were funded, stud-
ies should examine a combination of natural history, treatment, and quality of life 
parameters, especially the effectiveness of first-line TKI treatment.
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objeCtives: The first goal was to adapt an existing Austrian decision-analytic 
model for chronic myeloid leukemia (CML) treatment to the US-American health 
care context. Secondly, we updated the model with new data and further treat-
ment strategies to identify the most effective and most cost-effective strategy for 
the treatment of CML patients with different sequential tyrosine kinase inhibi-
tors (TKIs). Methods: We evaluated 18 different treatment strategies within the 
US-American setting in terms of survival, quality-adjusted survival and costs. For 
model parameters, data from literature, a US-American expert survey, the Utah 
Cancer Registry, and economic data from a US-American database were used. 
Evaluated treatment strategies included imatinib, dasatinib, nilotinib, bosutinib, 
ponatinib, stem-cell transplantation and chemotherapy. The Markov state-tran-
sition model was analyzed as a cohort simulation over a lifelong time horizon, 
a third-party payer perspective was adopted and a discount rate of 3% was used. 
Additionally, several deterministic and probabilistic sensitivity analyses were con-
ducted. Results: Imatinib without second-line TKI resulted in an incremental 
cost-utility ratio (ICUR) of $148,700/QALY gained (incremental cost-effectiveness 
ratio (ICER) of $128,800/Lys) compared to baseline strategy ‘chemotherapy’. Imatinib 
with second-line nilotinib yielded an ICUR of $217,100/QALY gained (ICER $242,200/
LY) compared to imatinib without second-line TKI. Imatinib followed by second-
line bosutinib had an ICUR of $331,300/QALY gained (ICER $265,100/LY) compared 
to imatinib followed by second-line nilotinib. Imatinib with second-line dasatinib 
produced an ICUR of $343,200/QALY gained (ICER $279,600/LY) compared to imatinib 
with second-line bosutinib. All remaining strategies were excluded due to domi-
nance. ICURs and ICERs obtained from the probabilistic sensitivity analysis deviated 
up to 6.5% (2.5%) compared to base-case ICURs (ICERs). ConClusions: Based on 
our analysis and current treatment guidelines, we recommend imatinib followed 
by second-line nilotinib as the most cost-effective treatment strategy. Our model 
results may support clinicians and patients in CML treatment decision making.
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objeCtives: To assess the cost-effectiveness of using brentuximab vedotin (BV) in 
treating relapsed or refractory Hodgkin Lymphoma compared to standard chemo-
therapy and allogeneic stem cell transplant in the Swedish health care setting. 
Brentuximab vedotin is a novel antibody drug conjugate targeting CD-30 and is 
indicated for treating relapsed/refractory Hodgkin Lymphoma. Methods: A Markov 
model with a lifetime horizon was constructed to compare BV to chemotherapy or 
allogeneic stemcell transplant (alloSCT). The analysis had a societal perspective 
and included lost productivity using a human capital approach. The model uses 
comparators relevant to Sweden and all epidemiological and cost parameters were 
based on Swedish sources. Both costs and effects were discounted at 3% according 
to Swedish guidelines. Clinical effectiveness for BV was based on pivotal clinical 
trial results and published data from the literature for the comparators relevant to 
the reimbursement authorities and to enable long term modelling. Outcomes were 
measured in QALYs. Uncertainty was addressed both through probabilistic sensi-
tivity analysis and one-way analyses of central variables. Results: Brentuximab 
vedotin dominated alloSCT (i. e a lower treatment cost and a better health outcome) 
and the ICER when compared to chemotherapy was SEK 419 000 (€ 47 000). One-way 
sensitivity analyses showed that the results were stable when central variables 
were varied. The probabilistic analysis also showed that brentuximab vedotin had 
a high probability of being the most cost-effective treatment at the accepted thresh-
old values for all scenarios. ConClusions: The ICERs calculated were all below 
commonly accepted willingness to pay for a QALY in Sweden for both comparator 
scenarios. Brentuximab vedotin is a cost effective treatment option for relapsed/
refractory Hodgkin Lymphoma in the Swedish health care setting.
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objeCtives: This study estimated the cost-utility of axitinib after sunitinib failure 
in adult patients with renal cell carcinoma. Total costs and quality adjusted life 
years accrued with axitinib was compared to everolimus, the only drug for second 
line treatment financed by the Portuguese National Health Service. Methods: 
A 4-week cycle Markov model with three health states (progression free, post 
progression, and death) was adapted to the Portuguese setting. In the absence of 
head-to-head clinical trials and the unfeasibility of a standard indirect comparison, 
relative efficacy was based on a previous simulated treatment comparison. Axitinib 
trial data on quality of life (utility) was used for the progression free stage and 
objeCtives: To identify the dominant scheme of mRCC second-line target treat-
ment (compare two alternatives – Axitinib and Everolimus). Methods: Based on 
the Markov model, the cost-effectiveness analysis was realized. Overall survival, 
annual survival rate, time to progression of disease and direct cost of mRCC treat-
ment was evaluated. Costs analysis included: costs of two target therapy lines 
(Sunitinib as a first-line in combination with Axitinib or Everolimus treatment); cost 
of 3 and 4 grade side effects compensation; cost of diagnosis and inpatient care; cost 
of disease progression; cost of palliative and best supportive care. Results: During 
the pharmacoeconomic analysis of Axitinib use as a second-line therapy for mRCC, 
it was found that this target therapy regimen would significantly increase the time 
to progression and the overall survival which amounted to 22,75 months, with an 
annual survival rate of 68%, 38% and 17% of patients following the first, second and 
third year of treatment, respectively. Despite the high cost of this treatment regimen, 
reaching 51.327 EUR at the horizon of ten year study, the treatment regimen includ-
ing Axitinib will be characterized by the lowest values of the cost-effectiveness 
ratio, reflecting the costs incurred by the health care system for patient’s life sav-
ing, and incremental cost-effectiveness ratio, which was less than willingness to 
pay threshold in Russia. ConClusions: It is shown, Axitinib use as second-line 
of target therapy in patients with mRCC is the most preferable treatment regimen 
then Everolimus from the pharmacoeconomic point of view.
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objeCtives: Demonstrate through an economic evaluation of cost-effectiveness 
that using Hydralazine LP magnesium valproate (Transkrip ®) associated with 
first-line chemotherapy in the treatment of persistent or recurrent metastatic 
stage IVB cervical cancer, type not candidates for surgery or radiotherapy is more 
effective than the alternatives available in Mexican health institutions: cisplatin 
with topotecan (CT), cisplatin with paclitaxel (CP), cisplatin with vinorelbine (CV), 
carboplatin with paclitaxel (CaP), paclitaxel (P), cisplatin and cisplatin with gem-
citabine © (CG). Methods: A cost-effectiveness analysis was developed, using 
a Markov model with a time horizon of 2 years divided into 24 monthly cycles, 
the measure of effectiveness was determined as the years gained free survival 
(PFS), being an advanced cancer is significant, only were measured direct medi-
cal costs, an analysis of incremental cost-effectiveness was performed. To test 
the robustness of the model a deterministic and probabilistic sensitivity analysis 
was performed. Results:  The cost per patient using therapy with hydralazine LP 
magnesium valproate (Transkrip ®) is $ 142,109.93, gaining 0.8846 years in 
Progression free survival this treatment was more effective but more expensive, 
paclitaxel had a cost of $ 26,988.64 with 0.3631 years in PFS, this therapy is less 
expensive but more effective than all comparators. The ICER of (Transkrip ®) was 
$ 220.757 pesos per year in PFS versus paclitaxel. ConClusions: The economic 
results of treatment of patients with metastatic cervical cancer, through an epige-
netic therapy with hydralazine LP magnesium valproate (Transkrip ®) over a time 
horizon of two years showed that hydralazine LP magnesium valproate (Transkrip 
®) is a cost effective alternative respect to comparators showed a greater response 
in years of progression-free survival and ICER below of 2 GDP.
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objeCtives: Value-of-Information analysis can help to guide decision about future 
research priorities: If and what further research is needed? Our aim was to guide 
decision regarding future outcomes research on parameters related to different 
regimens for chronic myeloid leukemia (CML). Methods: We updated a previously 
developed state-transition Markov model of CML, which evaluates seven treatment 
regimens including tyrosine kinase inhibitors, chemotherapy and stem cell trans-
plantation (SCT). We derived model parameters from published trials data, Austrian 
clinical, epidemiological, and economic data. We performed a cohort simulation over 
a lifetime horizon, adopted a societal perspective, and discounted costs and benefits 
at 3% annually. We calculated the expected value of perfect information (EVPI), 
partial perfect information (EVPPI), and the population EVPI (PEVPI). Additionally, 
we examined the expected value of sample information (EVSI) for different trial 
sizes. Results: Three strategies are on the efficiency frontier: imatinibàchemo-
therapy/SCT, nilotinibàchemotherapy/SCT (140,000 € /QALY) and nilotinibàdasat-
inibàchemotherapy/SCT (176,000 € /QALY). The EVPI for eliminating all uncertainty 
resulted in a curve with two peaks. One peak is around a WTP threshold of 150,000 
€ /QALY (EVPI 4,600 € ) and another peak is at 180,000 € /QALY (EVPI 7,700 € ). The PEVPI 
for Austria assuming a 10-year technology horizon was 2.5 million € (WTP 150,000 
€ /QALY) and 4.5 million € (WTP 180,000 € /QALY). EVPPI identified four parameters 
most responsible for decision uncertainty: duration of first-line therapy, probability 
of progressing from chronic phase to accelerated phase, probability of receiving a 
SCT, and the health-utility after SCT. The EVSI commented on the optimal study 
size for these parameters given the cost of obtaining information. ConClusions: 
Acquiring additional evidence could prove valuable for determining optimal treat-
